AGOURA HILLS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) — Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that ArtiShieldTM is now approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy), license number UK.AY-401/2018, for the treatment of various symptoms like fever and inflammation. ArtiShieldTM is in co-development with Windlas Biotech Pvt. Ltd., Mateon’s commercial partner for India. ArtiShieldTM is being evaluated against COVID-19 in ARTI-19- a phase IV study in India. ArtiShieldTM is designed to be a readily available and cost-effective agent to combat COVID-19, with Windlas providing the capability to manufacture the doses necessary to support this endeavor.